What to look out for at ESMO 2021
ESMO Congress 2022 - Biognosys
ESMO 2022: Interim Results for Treatment of Platinum-Resistant Ovarian Cancer with p62 Plasmid DNA Show Statistically Significant Changes in Progression-Free Survival
Abstracts | ESMO TAT 2022
ESMO Breast Cancer 2022
Poster Presented at the ESMO Immuno-Oncology Congress - Immunophotonics
EONS15 at ESMO 2022 Congress - EONS - The European Oncology Nursing Society
Owkin showcases five AI abstracts at ESMO, including how deep learning can predict KRAS from H&E slides with Amgen and Bergonie - Owkin
Poster Presented at the ESMO Immuno-Oncology Congress - Immunophotonics
DBPi at ESMO Congress'22 representing Prostate Cancer patient survey | DontBePatient Intelligence GmbH
ESMO Congress 2022
ESMO Congress 2022 - Incisive Project
ESMO Congress 2022 - Biognosys
Important New Data From EORTC Trials To Be Presented At ESMO 2022 2023 - EORTC
ESMO Congress 2022
ESMO CONGRESS 2022
2022 ESMO On-demand Presentations
Abstracts | ESMO Asia Congress 2022
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022 | Business Wire
Medflixs - ESMO CONGRESS 2022
J INTS BIO, poster presentation of further preclinical data of its Novel Oral 4th Generation EGFR-TKI 'JIN-A02' at the 2022 European Society for Medical Oncology Congress in Paris, France (ESMO 2022)
AdvanTIG-105: Ociperlimab + tislelizumab with chemotherapy in metastatic squamous and non-squamous NSCLC – BeiGene Medical
